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Abstract 
With the growing epidemic of obesity across the United States, adolescents and adults are using 
dietary supplements for the purpose of weight loss and to build muscle with the common 
misconception that these supplements are proven safe and effective by the government before 
they are available to consumers (Pomeranz, Barbosa, Killian, & Austin, 2015).  Since 
supplements with ephedrine are no longer allowed on the market due to serious health risks, 
manufacturers have reformulated their supplements to include ingredients that have a similar 
chemical structure and pharmacological properties as ephedrine and have advertised them as 
“ephedra-free” (Foster, 2013).  There is very limited national data available identifying 
associated risks or adverse events with ephedra-free supplements.  This became an area of 
clinical interest after a 20 year old female college student presented to the family planning office 
requesting to initiate an oral contraceptive and had reported the occasional use of over-the-
counter ephedra-free Xendarine for weight loss.  Her body mass index (BMI) indicated she was 
underweight; she had no previous medical history, an unremarkable family history, and the 
review of systems and physical examination was negative for any abnormal or pertinent findings.  
A literature review was conducted to identify what potential health risks have been associated 
with the use of ephedra-free weight loss products, which included randomized controlled trials 
and numerous case reports.  The research findings will be discussed, as they identify a strong 
association of serious cardiovascular and neurological health risks with prolonged use of 
ephedra-free weight loss products. 
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Potential Health Risks Associated with the Use of OTC Ephedra-Free Weight Loss Products 
Background 
Significant attention has been placed on the growing epidemic of obesity, which is 
defined as a body mass index (BMI) of 30 or greater.  Across the United States (U.S.), the Center 
for Disease Control and Prevention (CDC) has estimated a prevalence of obesity of 
approximately 25% or greater across a majority of the states (Moaaddeb, Tofade, & Bevins, 
2011).  With the expanding and readily available weight loss or dietary supplements advertised 
across numerous forms of media and sold over-the-counter (OTC) in various stores and online, 
more adolescents and adults are purchasing these supplements to assist with their personal 
weight loss goals and/or to build more muscle.  In fact, studies conducted among adults in the 
U.S. have identified that 17% have used supplements to improve their sports performance, while 
20.6% of women and 9.7% of men have used supplements advertised specific for weight loss 
(Pomeranz, Barbosa, Killian, & Austin, 2015).  In addition, a national survey conducted in 2002 
revealed that 29.1% of adolescents and young adults between the ages of 14 and 19 years of age 
reported using any form of dietary supplement within the last 30 days, while 10.7% reported a 
history of using dietary supplements for weight loss at some point (Pomeranz, Barbosa, Killian, 
& Austin, 2015).  Unfortunately, the growing use of dietary supplements across the U. S. is 
perpetuated by consumers misconception regarding their safety and efficacy, which is greatly 
highlighted by a national study identifying that two-thirds of its respondents believed that these 
supplements were not only safe and effective, but half of those respondents also believed these 
supplements were proven safe and effective by the federal government before being placed on 
the market (Pomeranz, Barbosa, Killian, & Austin, 2015). 
POTENTIAL HEALTH RISKS ASSOCIATED WITH THE USE OF 5 
 
 As a result of Congress passing the Dietary Supplement Health and Education Act 
(DSHEA) in 1994, the Food and Drug Administration (FDA) is no longer required to regulate or 
allowed to verify the safety or efficacy of any dietary supplement before it is placed on the 
market.  This has contributed to an industry with a growth of $32 billion a year.  The 
responsibility of verifying the safety of these dietary supplements is placed on the manufacturers 
and their adherence to good manufacturing practices. These manufacturers are only required to 
report any serious adverse events that result in hospitalization, disability or death (Pomeranz, 
Barbosa, Killian, & Austin, 2015).  A review of available national surveillance data obtained 
from 63 emergency departments (ED) from 2004 to 2013 revealed “an estimated 23,000 
emergency department visits in the United States every year are attributed to adverse events 
related to dietary supplements” (Geller et al., 2015, p. 1531), and of those adverse events, weight 
loss supplements account for 25.5% and involve cardiovascular manifestations of palpitations, 
tachycardia, and chest pain (Geller et al., 2015).  Potentially contributing to the limited national 
data on associated adverse events, healthcare providers are not always aware that their patients 
are consuming dietary supplements, nor do consumers associate any symptoms to these 
supplements, so most adverse events are never reported to the FDA (Geller et al., 2015; & 
Pomeranz, Barbosa, Killian, & Austin, 2015). 
Relative to this clinical topic, a 20 year old female college student presented as a new 
patient to the family planning office requesting to start an oral contraceptive.  She had no past 
medical history, and family history was negative for any clotting disorders, heart disease, 
neurological disorders or cancer.  Upon review of her current medications, she reported the use 
of OTC multivitamin, Midol as needed for menstrual cramps, Tylenol as needed for headaches, 
and ephedra-free Xenadrine occasionally for weight loss as needed.  Her body mass index of 
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17.2 indicated she was underweight, and she denied any associated symptoms or side effects 
related to this weight loss supplement.  Vital signs were all within normal limits and physical 
examination was negative for any pertinent or abnormal findings.  Due to safety concerns and 
unknown potential health risks regarding dietary supplements, she was instructed to discontinue 
use of Xenadrine.  With the federal government banning ephedrine-containing dietary 
supplements from the market in April 2004 due to the serious adverse events, this case highlights 
the need for research to identify any reported adverse events or potential health risks that have 
been associated with the use of OTC ephedra-free weight loss supplements (Stephensen & 
Sarlay, 2009).  Pertinent research findings will improve clinical awareness, knowledge, and 
competency regarding the use of these weight loss supplements in order to provide current and 
appropriate patient education regarding its use, appropriate monitoring should patients choose to 
continue to use these supplements despite medical advice, and improve reporting of adverse 
events to the FDA. 
Case Report 
Presenting as a new patient to the family planning office, L. J. is a 20 year old female 
requesting to start oral contraceptives to prevent unplanned pregnancies.  Upon review, her past 
medical history is negative for any medical conditions, surgeries, or hospitalizations.  Allergies 
include penicillin, and her current medication list includes the following: over-the-counter (OTC) 
ephedra-free Xenadrine as needed for weight loss; OTC multivitamin occasionally; OTC Midol 
for menstrual cramps as needed; and OTC Tylenol as needed for headaches.  She is up to date on 
recommended vaccinations, including the Human Papillomavirus (HPV) vaccine series.  Her 
reported reproductive history includes a menstrual cycle occurring every month and lasting about 
5 days in length without any heavy clots, and a last menstrual cycle that occurred on January 19, 
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2016.  She denies any history of pregnancies, any previous screenings or treatments for sexually-
transmitted infections (STIs), or any previous use of prescribed contraceptives.  She is 
heterosexual, is currently sexually active with the occasional use of condoms as a barrier method, 
and reports utilizing the emergency contraceptive Plan B once around this last New Years.  
Family history includes the following: hyperlipidemia and benign breast mass removed about 1 
year ago in her mother; blood clot following surgery in her father; no medical conditions among 
siblings (brother & sister); and no family history of clotting disorders.  Social history includes 
the following: currently attending college; single; denies any use of tobacco products or exposure 
to second hand tobacco smoke; reports current alcohol use of about 3 weekends per month with 
2-5 mixed drinks each time; and reports regular physical exercise daily. 
Measured vital signs were as follows: height of 67 inches; weight of 110 lbs (50 kg); 
blood pressure of 112/74; heart rate of 82; respiratory rate of 18; temperature of 98.5 F; and BMI 
of 17.2 (underweight).  Review of systems revealed whitish vaginal discharge without odor 
occasionally, but was otherwise proved negative for any other symptoms.  Upon physical 
examination, patient was alert, oriented x 3, affect stable, pleasant, cooperative, well-developed, 
well-nourished, and in no acute distress.  Examination of eyes revealed the following: pupils 
were equal, round, and reactive to light (PEERL); extraocular movements were intact (EOMI); 
and no discharge or erythema were noted.  Heart rate and rhythm were regular without murmur, 
gallop or rub.  Lung sounds were clear bilaterally without rales, rhonchi, or wheezing noted and 
breathing was unlabored.  Abdomen was flat, non-distended, and non-tender without any 
guarding, masses, organomegaly, and bowel sounds were normoactive in all 4 quadrants. 
 Laboratory testing included urine pregnancy test to verify pregnancy status prior to 
initiating oral contraception, as well as annual screening for chlamydia and gonorrhea per 
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clinical screening guidelines.  Diagnoses included initial encounter and prescription for 
contraceptives, negative pregnancy test, screenings for bacterial sexually transmitted infections 
(STIs), and high risk heterosexual behavior.  Documented counseling that occurred during 
encounter included family planning and forms of available contraception with risks and benefits 
of each method, education and prevention of STIs, healthy body mass index (BMI), healthy 
dietary and lifestyle modifications to maintain healthy weight and general health, and potential 
risks related to use of over-the-counter weight loss supplements. 
 With confirmation of negative pregnancy test and no identified risks factors or 
contraindications, an oral monophasic combined oral contraceptive (COC) was initiated per 
patient’s preference.  She was instructed to use condoms as a barrier method for the first week of 
oral contraceptive, as well as with all sexual encounters for STI prevention.  Patient will be 
contacted regarding results of STI screenings when made available.  She was instructed to 
monitor for signs of abdominal pain, chest pain, headaches, visual changes/disturbances, or 
severe leg pain due to risks of blood clots while taking COCs, and to seek medical attention if 
these symptoms should develop.  Common side effects or reactions that may occur and should 
resolve were discussed and included nausea, vomiting, breast tenderness, and bleeding 
irregularities.  Discussed clinical recommendations for cervical screenings after the age of 21 
years old, and monthly self-breast examinations were recommended for her own body 
awareness.  Encouraged to continue regular physical activity, maintain a well-balanced meal and 
adequate hydration in regards to overall health and weight management.  Informed of current 
BMI, which indicates she’s underweight, and highly encouraged to discontinue the use OTC 
Xenadrine due to potential health risks.  Tobacco use was discussed and highly discouraged, as 
well as encouraged to limit alcohol use due to identified high risk sexual behaviors and safety 
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concerns correlated with excessive alcohol intake.  Will complete a follow-up appointment in 
three months to evaluate adherence and adjustment to medication, as well as discuss any 
questions, concerns, or side effects, and will anticipate scheduling an annual physical 
examination with clinical Pap smear and breast examination after reaches 21 years of age in 1 
year. 
Literature Review 
As health care providers, it is our responsibility to initially evaluate the quality of 
research prior to implementing it into our clinical practice.  To assist with evaluating various 
studies and research, the evidence-leveling system created by the American Association of 
Critical Care Nurses (AACN) in 2008-2009 was used in this process, which identifies six 
separate levels of evidence with Level A as the highest level of evidence (e.g. meta-analysis and 
meta-synthesis) and Level M as the lowest level of evidence (e.g. manufacturer 
recommendations) (Armola et al., 2009).  Each research study that is discussed will have a level 
of evidence identified. 
Online resources available through the University of North Dakota’s (UND) Harley E. 
French Library of the Health Sciences was utilized to complete the online literature search 
required to address the identified area of clinical interest and included CINAHL, PubMed, and 
the Cochrane Library.  The main concepts or terms utilized during this literature search included 
“ephedra-free”, “weight loss products”, and “weight loss products, dietary supplements”; 
however, the term “ephedra-free” produced more specific results, and due to limited available 
data, no additional limitations in regards to date of publication, etc., were applied.  At the 
conclusion of this literature search, fourteen research articles, including 3 randomized clinical 
trials (Level B evidence) and 11 case reports (Level E evidence) were identified as applicable to 
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the chosen research question of: what potential health risks have been associated with the use of 
OTC ephedra-free weight loss products. 
This area of clinical interest was deemed pertinent upon completing an initial encounter 
with a 20 year old female college student that had presented as a new patient to the family 
planning office requesting to start an oral contraceptive.  With the patient’s medical history, 
family history, review of systems and physical examination unremarkable for any pertinent 
findings or contraindications, an oral contraceptive was initiated.  However, the occasional use of 
OTC ephedra-free Xendarine was reported upon review of her current medications, which she 
believed were safe to consume and had denied any associated symptoms or side effects.  With 
the well-known banning of ephedrine-containing dietary supplements from the market in 2004 
due to its serious adverse events, this case highlights the need for further research to identify any 
reported adverse events or potential health risks that have been associated with the use of OTC 
ephedra-free weight loss supplements in order to improve clinical awareness, knowledge, and 
competency regarding the use of these weight loss supplements to provide current and 
appropriate patient education regarding its use, monitoring should patients choose to continue 
these supplements despite medical advice, and improve reporting of adverse events to the FDA. 
As mentioned previously, manufacturers of dietary supplements are no longer allowed to 
produce products containing the ingredient ephedrine due to the serious cardiovascular and 
neurological risks and adverse events that were identified.  This resulted in the production of 
“ephedra-free” supplements using a combination of ingredients, such as guarana, bitter orange or 
Citrus aurantium, ma huang, cocoa, Coleus forskolii and synephrine as substitutes for ephedrine.  
These ingredients have been found to have similar chemical and pharmacological properties as 
its predecessor ephedrine, yet there has been few research studies that have evaluated the safety 
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of these products (Foster et al., 2013; Moaddeb, Tofade, & Bevins, 2011; Retamero, Rivera, & 
Murphy, 2011). 
Unfortunately, only a few randomized controlled trials (RCTs) have been conducted to 
determine the adverse effects of ephedra-free weight loss supplements required to provide 
sufficient evidence to prove their efficacy and safety.  Results from a RCT published in 2005 
determined there was no significant change in either blood pressure or systemic vascular 
resistance index (SVRI) among healthy volunteers that were administered a single dose of 
Metabolife Ephedra-Free (Min, McBride, Kardas, Ismali, Sinha, Kluger, & White, 2005).  In 
contrast, significant increases in blood pressure measurements and irregular atrial/ventricular 
events were noted on an electrocardiograph (ECG) compared to baseline readings following the 
administration of multiple daily doses of several different ephedra-free products, as evidenced by 
two additional randomized studies (Foster et al., 2013; & Haller, Benowitz, & Jacob, 2005).  
Other associated symptoms included nausea and vomiting that were linked to a heavy 
contamination of bacillus species among two separate supplements (Foster, 2013).  These 
“findings suggests that prolonged use of certain “ephedra-free” supplements may alter cardiac 
electrophysiology” compared to a one-time dose, as well as have the potential risks associated 
with herb-drug interactions and microbial contamination (Foster et al., 2013, p 271). 
Furthermore, numerous case reports of associated adverse effects of rhabdomyolysis, 
psychosis, hypertensive urgency with presenting blood pressure of 234/130, malignant 
hypertension with aortic dissection, malignant hypertension with hypertensive retinopathy, 
ventricular fibrillation, ST-segment elevation myocardial infarction, exercise-induced syncope 
with QT prolongation, left middle cerebral artery vasospasm with stroke, and ischemic stroke 
have been associated with ephedra-free supplements since they became available to consumers.  
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In most of these cases, symptoms related to the adverse event developed after consuming the 
supplements for a prolonged period of time that ranged from a couple of weeks to numerous 
months.  Among these reported cases, most had no predisposing medical history that would have 
accounted for or contributed to the development of these adverse events, and symptoms resolved 
without recurrence after the discontinuation of the ephedra-free supplement.  In these patient 
cases, the probability that the adverse events were, indeed, associated with the patient’s reported 
use of an ephedra-free supplement prior to the onset of symptoms was established with the use of 
the clinical tool Naranjo adverse drug reaction probability scale (Ahmed, 2009; Bouchard, 
Howland, Greller, Hoffman, & Nelson, 2005; Burke, Seda, Allen, & Knee, 2007; Carol, 2013; 
Holmes & Tavee, 2008; Moaddeb, Tofade, & Bevins, 2011; Nasir, Durning, Fergunson, Barold, 
& Haigney, 2004; Retamero, Rivera, & Murphy, 2011; Stephenson & Sarlay, 2009; Thomas, 
Munir, McIntyre, & Ferguson, 2009; & Willis, Moawad, Hartzell, Iglesias, & Jackson, 2006).   
Even though case reports have limited ability to identify causation, the pertinent research 
findings gained from the available randomized controlled trials (RCTs) and numerous case 
reports found in medical literature establish a strong association of serious cardiovascular and 
neurological health risks with the prolonged use of ephedra-free weight loss supplements or 
products that are similar to those previously reported with ephedrine, which has clinical 
implications for the safety of its consumers and our patients. 
Learning Points 
 In conclusion, research findings have established a strong association of serious 
cardiovascular and neurological health risks with the prolonged use of ephedra-free weight loss 
supplements or products.  It is the responsibility and recommendation for all healthcare providers 
to ask patients about their use of supplements and document with each encounter, as well as 
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provide education regarding the use of dietary supplements and associated health risks that have 
been identified.  Since the Food and Drug Administration (FDA) is no longer required or allowed 
to verify the safety and efficacy of dietary supplements before they are released on the market, it 
is imperative that healthcare providers continue to monitor and report any adverse events to the 
FDA, which can be completed online through the adverse event reporting program known as 
MedWatch located on the FDA’s website.  Increased reporting of adverse events will not only 
help the FDA identify any safety risks related to these supplements, but it also provides the 
opportunity to help advocate for improved regulation of dietary supplements by the FDA.    
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